Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01716247 · ClinicalTrials.gov registry record · NA
Comparison of Contrast Enhanced Mammography to Breast MRI in Screening Patients at Increased Risk for Breast Cancer
A NA study of Women at Increased Risk for Developing Breast Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT01716247 is a NA study of Women at Increased Risk for Developing Breast Carcinoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 1,000 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01716247, a NA study of Women at Increased Risk for Developing Breast Carcinoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if Contrast Enhanced Spectral Mammography (CESM) will be able to detect smaller/earlier breast cancers as well as breast MRI can.
Conditions Studied
Interventions
- OTHER Mammography (CESM) and MRI
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2012-10 |
| Est. Completion | 2018-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01716247
The ClinicalTrials.gov registry entry for NCT01716247 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Women at Increased Risk for Developing Breast Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Mammography (CESM) and MRI is the first listed.
NCT01716247 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01716247 about?
NCT01716247 is a clinical study titled "Comparison of Contrast Enhanced Mammography to Breast MRI in Screening Patients at Increased Risk for Breast Cancer". The purpose of this study is to determine if Contrast Enhanced Spectral Mammography (CESM) will be able to detect smaller/earlier breast cancers as well as breast MRI can.
What is the current status of trial NCT01716247?
This trial is currently completed. It is a NA study. The enrollment target is 1,000 participants. The study started on 2012-10. Estimated completion is 2018-06.
What conditions does trial NCT01716247 study?
This clinical trial studies the following conditions: Women at Increased Risk for Developing Breast Carcinoma.
What interventions are being tested in trial NCT01716247?
The interventions under investigation include: Mammography (CESM) and MRI (OTHER).
Who is sponsoring clinical trial NCT01716247?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01716247 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.